Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of anemia in low-risk myelodysplastic syndromes with epoetin beta
2009-011161-87Phase 2Active
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Nov 2009
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of epoetin beta in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Erythroid response at 12 weeks, Erythroid response at 24 weeks and 1 more. Started Nov 2009; status: active.
02
Drugs
epoetin beta
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2009-011161-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011161-87.